[1] Zaidi MY, Maithel SK.Updates on gallbladder cancer management[J]. Curr Oncol Rep,2018,20(2):21.
[2] Ethun CG, Postlewait LM, Le N, et al.Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. JAMA Surg,2017,152(2):143-149.
[3] Addeo P, Centonze L, Locicero A, et al.Incidental gallbladder carcinoma discovered after laparoscopic cholecystectomy: identifying patients who will benefit from reoperation[J]. J Gastrointest Surg,2018,22(4):606-614.
[4] Creasy JM, Goldman DA, Gonen M, et al.Predicting residual disease in incidental gallbladder cancer: risk stratification for modified treatment strategies[J]. J Gastrointest Surg,2017,21(8):1254-1261.
[5] 田远虎. 腹腔镜胆囊切除术术中或术后发现意外胆囊癌的外科治疗[J]. 中华外科杂志,2015,53(2):135-139.
[6] Duffy A, Capanu M, Abou-Alfa GK, et al.Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre(MSKCC)[J]. J Surg Oncol,2008, 98(7):485-489.
[7] Du J, Yang XW, Wen ZJ, et al.Relationship between prognosis and time interval from cholecystectomy to reo-peration in postoperative incidental gallbladder carcinoma[J]. Chin Med J (Engl),2018,131(20):2503-2505.
[8] Lee H, Kwon W, Han Y, et al.Optimal extent of surgery for early gallbladder cancer with regard to long-term survival: a meta-analysis[J]. J Hepatobiliary Pancreat Sci,2018,25(2):131-141.
[9] 段安琪, 邱应和, 易滨, 等. 意外胆囊癌在腹腔镜切除术中或术后的处理对策[J]. 临床和实验医学杂志,2016,15(1):62-64.
[10] Goetze TO, Paolucci V.The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry[J]. Surg Endosc,2012,26(5):1382-1389.
[11] Sternby Eilard M, Lundgren L, Cahlin C, et al.Surgical treatment for gallbladder cancer - a systematic literature review[J]. Scand J Gastroenterol,2017,52(5):505-514.
[12] 孙静锋, 赵何伟, 郑苏文, 等. 根治性切除及单纯胆囊切除对Ⅱ期胆囊癌疗效的Meta分析[J]. 中国肿瘤外科杂志,2013,5(1):33-36.
[13] Ito H, Ito K, D'Angelica M, et al. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment[J]. Ann Surg,2011,254(2):320-325.
[14] 程石. 重视意外胆囊癌再次手术的规范[J]. 临床外科杂志,2017,25(6):423-425.
[15] Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer an international multicenter study[J]. Ann Surg,2015,261(4):733-739.
[16] Vinuela E, Vega EA, Yamashita S, et al.Incidental gallbladder cancer: residual cancer discovered at oncologic extended resection determines outcome: a report from high- and low-incidence countries[J]. Ann Surg Oncol,2017,24(8):2334-2343.
[17] 中华医学会外科学分会胆道外科学组. 胆囊癌诊断和治疗指南(2015版)[J]. 中华消化外科杂志,2016,14(3):411-419.
[18] Piccolo G, Piozzi GN.Laparoscopic radical cholecystectomy for primary or incidental early gallbladder cancer: the new rules governing the treatment of gallbladder cancer[J]. Gastroenterol Res Pract,2017,2017:8570502.
[19] Berger-Richardson D, Chesney TR, Englesakis M, et al.Trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer: A systematic review[J]. Surgery,2017,161(3):618-627.
[20] Maker AV, Butte JM, Oxenberg J, et al.Is port site resection necessary in the surgical management of gallbladder cancer?[J]. Ann Surg Oncol,2012,19(2):409-417.
[21] Ethun CG, Postlewait LM, Le N, et al.Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. J Surg Oncol,2017,115(7):805-811.
[22] 汤朝晖, 田孝东, 魏妙艳, 等. 美国癌症联合委员会胆道恶性肿瘤分期系统(第8版)更新解读[J]. 中国实用外科杂志,2017,37(3):248-254.
[23] Lee W, Jeong CY, Jang JY, et al.Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study[J]. Surgery,2017,162(3):515-524.
[24] 汤朝晖, 刘颖斌, 全志伟. 肿瘤分期对胆囊癌术式选择及预后判断临床意义研究[J]. 中国实用外科杂志,2011,31(3):224-227.
[25] Smith-Cohn MA, Gill D, Voorhies BN, et al.Case report: pembrolizumab- induced type 1 diabetes in a patient with metastatic cholangiocarcinoma[J]. Immunotherapy,2017,9(10):797-804.
[26] Czink E, Kloor M, Goeppert B, et al.Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer[J]. Cold Spring Harb Mol Case Stud,2017,3(5):a001974.
[27] 陈亚进, 陈贤清. 程序性细胞死亡蛋白-1及其配体抑制剂在胆道肿瘤治疗中的现状与前景[J]. 中华消化外科杂志,2018(3):219-224.
